Wellmune Linked to Fewer Cold-Flu Symptoms in Study
The ingredient reduced cold and flu symptoms by 43 days compared to placebo.
Wellmune WGP, a yeast beta-glucan ingredient from Biothera (Eagan, MN), has impressed in a new study on medical students during cold-flu season. The ingredient reduced cold and flu symptoms by 43 days compared to placebo. Results are now published in the June issue of the journal Nutrition.
Researchers at Southampton University Medical School assigned 100 healthy med students to 90 days of Wellmune WGP (250 mg daily) or placebo. Over the course of the study, 24 cases of upper respiratory tract infection were confirmed by medical staff-12 in each test group-but the Wellmune WGP group experienced fewer days with actual symptoms.
“The results are consistent with eight other clinical studies regarding the immune support effects of Wellmune WGP,” says Don Cox, PhD, senior vice president of research and development at Biothera.
The yeast beta-glucan is currently a focus of the EU’s FibeBiotics immune health project.
